Axiom Investors
BBIO icon

Axiom Investors’s BridgeBio Pharma BBIO Stock Holding History

Axiom Investors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.67M Sell
76,148
-123,840
-62% -$8.67M 0.05% 107
2026
Q1 		$14.9M Sell
199,988
-7,531
-4% -$546K 0.17% 55
2025
Q4 		$15.9M Buy
207,519
+97,622
+89% +$6.41M 0.14% 62
2025
Q3 		$5.71M Buy
+109,897
New +$5.36M 0.04% 96

Other funds holding BBIO

Jupiter Topco
Jupiter Topco New York $245B AUM
Kohlberg Kravis Roberts & Co
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Axiom Investors's BBIO Position: Q2 2026 in Review

Axiom Investors reduced its BridgeBio Pharma (BBIO) stake by 62% in Q2 2026, selling an estimated $8.67M and leaving 76,148 shares worth $5.67M. The position accounts for 0.05% of the portfolio, ranked #107.

Axiom Investors first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $15.9M in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Axiom Investors held 76,148 shares of BridgeBio Pharma worth $5.67M as of Q2 2026.
  • Axiom Investors sold 123,840 BridgeBio Pharma shares in Q2 2026, an estimated $8.67M.
  • BridgeBio Pharma made up 0.05% of Axiom Investors's portfolio in Q2 2026, its #107 holding.
  • Axiom Investors first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • Axiom Investors's BridgeBio Pharma position peaked at $15.9M in Q4 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Axiom Investors's 13F filing for Q2 2026, filed 12 Aug 2026.